Actively Recruiting
Evaluating Intrathecal Mivelsiran for Early-Stage Down Syndrome-Associated Alzheimers Disease in Adults A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
Led by Alnylam Pharmaceuticals · Updated on 2026-10-13
58
Participants Needed
10
Research Sites
62 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of mivelsiran in adults aged 40 to 55 years who have early-stage Down Syndrome-Associated Alzheimers Disease DS-AD. This Phase 2 study focuses on understanding the safety, tolerability, and pharmacodynamics of intrathecally administered mivelsiran. The study is sponsored by Alnylam Pharmaceuticals and involves a randomized, placebo-controlled design with quadruple masking to ensure unbiased results. Participants will receive multiple doses of either low or high amounts of mivelsiran, or a placebo, administered directly into the spinal canal. The study includes two main periods a 24-month double-blind phase where neither participants nor researchers know the group assignments, followed by an optional 12-month open-label extension where all participants may receive mivelsiran. This approach allows thorough assessment of the treatment effects over an extended timeframe. During the study, participants will undergo evaluations of brain amyloid burden using imaging, along with measurements of relevant proteins in cerebrospinal fluid and plasma. Cognitive function will also be monitored. Safety assessments include tracking adverse events throughout both the double-blind and extension periods. Overall participation may last up to 39 months, including screening, treatment, and safety follow-up to ensure comprehensive data collection on the interventions impact.
CONDITIONS
Brief Title
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Research Team
A
Alnylam Clinical Trial Information Line
A
Alnylam Clinical Trial Information Line
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here